Keywords: teva, loses, exclusivity, pravastatin, fda, israel, pharmaceuticals

Teva loses exclusivity on pravastatin, US FDA

Article | 18 July 2005

Print This

Israel's Teva Pharmaceuticals has received a letter from the US Food and Drug Administration casting doubt over the 180-day exclusivity ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in